Literature DB >> 17506474

Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants.

Berrin Esen1, Nilay Coplu, Demet Kurtoglu, Aysegul Gozalan, Levent Akin.   

Abstract

Acute pertussis infection among adults can cause its transmission to the larger population, especially to infants and young children, who can develop severe disease. In order to determine an age-dependent pertussis immune response, anti-pertussis toxin (PT) antibody was detected by the indirect enzyme-linked immunosorbent assay (ELISA) method in serum samples from 2,085 healthy subjects ranging in age from 6 months to > or = 60 years. Also included in the evaluation were responses to a questionnaire including sociodemographic characteristics, vaccination, and infection history. Titers of 50-99 ELISA units (EU)/mL and of > or = 100 EU/mL were accepted as indicative for recent exposure or infection. In addition, 30 EU/mL was estimated to be a sufficient titer in women of childbearing age to protect their newborns until administration of their first dose of pertussis vaccine. After the age of 4-5 years, presence of high-titered antibodies that increase with age might be a reflection of circulating infection and indicate the magnitude of the threat to infants. According to the questionnaires, in the groups younger than 15 years old, three to four doses of diphtheria toxoid-whole cell pertussis-tetanus toxoid (DwPT) were administered in 47.2 to 77.4%, 91.2 to 100.0%, and 83.5 to 100.0% of participants in Diyarbakir, Samsun, and Antalya, respectively. In addition, up to half of the expectant mothers we studied lacked a sufficient level of estimated antibody titers. To protect infants from life-threatening pertussis infection, improving vaccination coverage to ensure herd immunity and uniformly establishing coverage throughout the country are essential. Furthermore, revaccination with acellular vaccine for schoolchildren as well as for the households of pregnant women is recommended. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17506474      PMCID: PMC6648994          DOI: 10.1002/jcla.20127

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  15 in total

Review 1.  How to make sense of pertussis immunogenicity data.

Authors:  P Olin; H O Hallander; L Gustafsson; E Reizenstein; J Storsaeter
Journal:  Clin Infect Dis       Date:  2001-12-15       Impact factor: 9.079

Review 2.  Clinical practice. Pertussis--not just for kids.

Authors:  Erik L Hewlett; Kathryn M Edwards
Journal:  N Engl J Med       Date:  2005-03-24       Impact factor: 91.245

3.  [Standardization of an in-house ELISA for pertussis serology and its application in a seroepidemiological study].

Authors:  Nilay Cöplü; Berrin Esen; Demet Kurtoğlu; Aysegül Gözalan; Kikuko Miyamura; Iwao Yoshida
Journal:  Mikrobiyol Bul       Date:  2005-07       Impact factor: 0.622

4.  Determination of antibodies to pertussis toxin in working reference preparations of anti-pertussis sera from various national control laboratories.

Authors:  E Relyveld; N H Oato; M Huet; R K Gupta
Journal:  Biologicals       Date:  1992-03       Impact factor: 1.856

5.  Seroprevalance of Bordetella pertussis antibodies among healthy adolescent girls in Edirne.

Authors:  Ulfet Vatansever; Nilay Cöplü; Naci Oner; Cemile Sönmez; Serap Karasalihoglu; Demet Kurtoglu; Berrin Esen; Galip Ekuklu
Journal:  Swiss Med Wkly       Date:  2005-09-03       Impact factor: 2.193

6.  Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study.

Authors:  P García-Corbeira; R Dal-Ré; L Aguilar; J García-de-Lomas
Journal:  Vaccine       Date:  2000-04-28       Impact factor: 3.641

7.  Measles seroepidemiology in 3 cities in Turkey.

Authors:  Aysegul Gozalan; Gulay Korukluoglu; Demet Kurtoglu; Kikuko Miyamura; Neziha Yilmaz; Morihiro Morita; Berrin Esen; Levent Akin
Journal:  Saudi Med J       Date:  2005-12       Impact factor: 1.484

8.  Adolescent and adult pertussis vaccination: computer simulations of five new strategies.

Authors:  Annelies Van Rie; Herbert W Hethcote
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

9.  Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum.

Authors:  C Mary Healy; Flor M Munoz; Marcia A Rench; Natasha B Halasa; Kathryn M Edwards; Carol J Baker
Journal:  J Infect Dis       Date:  2004-06-14       Impact factor: 5.226

10.  Community-based seroepidemiology of tetanus in three selected provinces in Turkey.

Authors:  Demet Kurtoglu; Aysegul Gozalan; Nilay Coplu; Kikuko Miyamura; Morihiro Morita; Berrin Esen; Levent Akin
Journal:  Jpn J Infect Dis       Date:  2004-02       Impact factor: 1.362

View more
  5 in total

1.  Recent findings on pertussis epidemiology in Turkey.

Authors:  D Dilli; I Bostanci; Y Dallar; T Buzgan; H Irmak; M A Torunoğlu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

2.  Epidemiology of pertussis in adolescents and adults in Turkey.

Authors:  A Karagul; D Ogunc; K Midilli; G Ongut; B Ozhak Baysan; L Donmez; D Daglar; M A Kuskucu; A Bingol; O Ozbudak; D Colak; F Gunseren
Journal:  Epidemiol Infect       Date:  2014-12-19       Impact factor: 4.434

3.  Social contact patterns of infants in deciding vaccination strategy: a prospective, cross-sectional, single-centre study.

Authors:  M M Oguz; A D Camurdan; F N Aksakal; M Akcaboy; E Altinel Acoglu
Journal:  Epidemiol Infect       Date:  2018-05-09       Impact factor: 4.434

Review 4.  Pertussis. A reemerging and an underreported infectious disease.

Authors:  Muhammad A Syed; Noureen F Bana
Journal:  Saudi Med J       Date:  2014-10       Impact factor: 1.484

5.  Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study.

Authors:  C Conde-Glez; E Lazcano-Ponce; R Rojas; R DeAntonio; L Romano-Mazzotti; Y Cervantes; E Ortega-Barría
Journal:  Epidemiol Infect       Date:  2013-06-05       Impact factor: 4.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.